Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

A Study in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01847092
Recruitment Status : Completed
First Posted : May 6, 2013
Results First Posted : May 27, 2020
Last Update Posted : May 27, 2020
Information provided by (Responsible Party):

Brief Summary:
The purpose of this study is to determine if the study drug is safe, tolerable and active in reducing albuminuria in patients with Chronic Kidney Disease with Type 2 Diabetes.

Condition or disease Intervention/treatment Phase
Chronic Kidney Disease Type 2 Diabetes Mellitus Drug: AZD1722 Drug: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 154 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: An Exploratory Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Design Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of AZD1722 in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria
Study Start Date : May 2013
Actual Primary Completion Date : March 2015
Actual Study Completion Date : April 2015

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: AZD1722
AZD1722 in 5, 15, 30, or 60 mg capsules. Starting dose is 15 mg BID PO for 12 Weeks
Drug: AZD1722
Placebo Comparator: Placebo
Placebo capsule BID PO for 12 Weeks
Drug: Placebo
Placebo for AZD1722

Primary Outcome Measures :
  1. Changes in Urine Albumin to Creatinine Ratio (UACR) [ Time Frame: Week 12 ]
    The difference between tenapanor and placebo in the change in UACR from baseline to the end of 12 weeks of treatment

Secondary Outcome Measures :
  1. Change in Estimated Glomerular Filtration Rate (mL/Min/1.73 m2) From Baseline to Week 12 Endpoint [ Time Frame: 12 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Males or females aged 18 to 80 years, inclusive.
  • Body mass index between 18 and 45 kg/m2, inclusive.
  • Type 2 diabetes mellitus and receiving ≥1 glucose lowering medication for at least 3 months prior to randomization
  • Stage 3 CKD
  • MSSBP ≥130 mmHg
  • Urinary albumin: mean UACR ≥ 200 mg/g

Exclusion Criteria:

  • Urinary albumin: UACR > 3500 mg/g
  • History of a renal transplant
  • MSSBP >180 mmHg or a MSDBP of >120 mmHg on two occasions during screening or run-in periods
  • History of inflammatory bowel disease or diarrhea predominant irritable bowel syndrome

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01847092

Layout table for location information
United States, Colorado
Creekside Endocrine Associates PC
Denver, Colorado, United States, 80209
Sponsors and Collaborators
Layout table for additonal information
Responsible Party: Ardelyx Identifier: NCT01847092    
Other Study ID Numbers: D5610C00001
First Posted: May 6, 2013    Key Record Dates
Results First Posted: May 27, 2020
Last Update Posted: May 27, 2020
Last Verified: May 2020
Keywords provided by Ardelyx:
Additional relevant MeSH terms:
Layout table for MeSH terms
Kidney Diseases
Renal Insufficiency, Chronic
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Urologic Diseases
Renal Insufficiency
Urination Disorders
Urological Manifestations